Intravesical Instillation of Bacille Calmette-Guérin for Superficial Bladder Cancer: Cost-Effectiveness Analysis

Urology

Volumn 69, Issue 2, 2007, Pages 275-279

  Uchida, Atsushi ^a   Yonou, Hiroyuki ^a   Hayashi, Eiri ^a   Iha, Kei ^a   Oda, Masami ^a   Miyazato, Minoru ^a   Oshiro, Yoshinori ^a   Hokama, Sanehiro ^a   Sugaya, Kimio ^a   Ogawa, Yoshihide ^a  

^a UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CYSTECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33847078483     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.10.017     Document Type: Article

References (18)

1. Shelley M.D., Wilt T.J., Court J., et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
2. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325 (1991) 1205-1209
3. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13 (1995) 1404-1408
4. Lundholm C., Norlen B.J., Ekman P., et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 156 (1996) 372-376
5. Bohle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-687
6. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 56 (2004) 65-72
7. In: Sobin L.H., and Wittekind C. (Eds). TNM Classification of Malignant Tumors. 5th ed. (1997), John Wiley & Sons, New York
8. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
9. Melekos M.D., Chionis H.S., Paranychianakis G.S., et al. Intravesical 4′-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer 72 (1993) 1749-1755
10. Malmstrom P.U., Wijkstrom H., Lundholm C., et al. for the Swedish-Norwegian Bladder Cancer Study Group: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 161 (1999) 1124-1127
11. Kaasinen E., Rintala E., Hellstrom P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
12. Stavropoulos N.E., Hastazeris K., Filiadis I., et al. Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer-results of a controlled prospective study. Scand J Urol Nephrol 36 (2002) 218-222
13. Joudi F.N., Smith B.J., O'Donnell M.A., et al. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 62 (2003) 1083-1088
14. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
15. Bassi P., Spinadin R., Carando R., et al. Modified induction course: a solution to side-effects?. Eur Urol 37 suppl 1 (2000) 31-32
16. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. The side effects of bacillus Calmette-Guérin in the treatment of Ta, T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial. Eur Urol 44 (2003) 423-428
17. Shahin O., Thalmann G.N., Rentsch C., et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
18. Okamura K., Ono Y., Kinukawa T., et al. Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94 (2002) 2363-2368